Lv3
360 积分 2023-06-19 加入
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
2天前
已完结
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer
1个月前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Targeting KRAS in cancer
3个月前
已完结
First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial
4个月前
已完结
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
7个月前
已关闭
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
9个月前
已完结
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer
9个月前
已完结
Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
11个月前
已完结
皖公网安备34019202002308
